NanoGroup S.A. is launching the next phase of research with a proprietary innovative organ perfusion fluid

After announcing positive results from preliminary studies comparing kidneys perfused with NanOX 10 and NanOX 20 fluids with the current standard used in transplantation, NanoGroup S.A. has begun the next phase of research on the way to marketing its solution. The study, which kicked off on February 6, will take about six weeks.

The goal of the NanoGroup-led OrganFarm project is to implement a new extracorporeal organ storage system to extend the possible shelf life of organs for transplantation. Following a successful study conducted at the Jan Kielanowski Institute of Animal Physiology and Nutrition of the Polish Academy of Sciences by a team led by Prof. dr. hab. med. Maciej Kosieradzki and Dr. hab. n. med. Piotr Domagała of the Department of General and Transplant Surgery at the University Clinical Center of Medical University of Warsaw, NanoGroup S.A. has moved to the next stage of work on its system.

The purpose of the designed study is to reflect one of the situations occurring in transplant practice related to the procurement and storage of an organ for transplantation. The simulation assumes uncontrolled cardiac arrest in a donor in an out-of-hospital setting – the arrival of the emergency medical team in under 30 minutes, undertaking resuscitation with restoration of circulation at a low level, and, once the decision is made to end it, deciding to harvest the organ for transplantation. In such a scenario, the time for organ transplantation is extremely short due to the limitations of being able to store such an organ. NanoGroup S.A. is currently working on the possibility of extending this time.

Nano group

– With the research we have conducted so far on our organ storage system, we have scientific confirmation that we are on track to significantly improve organ survival and the ability to continue using organs for transplantation, compared to fluids currently on the market. I am pleased that we can announce the beginning of the next research stage, the expected positive result of which will constitute another important step in bringing our technology to market. Of course, further research to verify the effectiveness of our technology in various simulations is still ahead of us. We see a lot of potential in it and are looking forward to the results of the ongoing research work ,” comments Piotr Mierzejewski, Vice President of the Management Board of NanoGroup S.A..